WO2004017040A2 - Multi-dimensional chromatography system for proteomics - Google Patents
Multi-dimensional chromatography system for proteomics Download PDFInfo
- Publication number
- WO2004017040A2 WO2004017040A2 PCT/US2003/025367 US0325367W WO2004017040A2 WO 2004017040 A2 WO2004017040 A2 WO 2004017040A2 US 0325367 W US0325367 W US 0325367W WO 2004017040 A2 WO2004017040 A2 WO 2004017040A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- column
- proteins
- sample
- protein
- fractions
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/38—Flow patterns
- G01N30/46—Flow patterns using more than one column
- G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
- G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Definitions
- the present invention relates generally to methods and compositions for identifying biomolecules present in a biological sample. More specifically, the present invention relates to mass spectrometry-based methods and compositions for identifying proteins present in a body fluid.
- proteome The analysis of a proteome involves the separation of the proteins in a sample followed by the identification of the resolved proteins, a challenging task given the tremendous chemical heterogeneity in virtually all parameters that can be measured. For example, some cytokines weigh between 1 and 2kD, while large muscle proteins weigh close to lOOOkD. Some proteins are very soluble and may also be present at high concentration in aqueous media (e.g. albumin, 40mg/mL in plasma), while some membrane proteins have more than 75% of their amino acids buried in the phospholipid bilayer and are thus not amenable to studies in aqueous solvents.
- aqueous media e.g. albumin, 40mg/mL in plasma
- proteins are present in extremely divergent concentrations in cells, ranging from 100 to 100,000,000 molecules per cell.
- the large range of concentration presents considerable difficulties for protein analysis since available methods tend to lack the resolution to detect non-abundant proteins - that is, current methods are often overloaded with protein if practiced with the large sample volumes that would be required in order to detect low abundance proteins and peptides.
- the term "dynamic range" is used in the art in the context of biological samples, referring to the ratio of the concentrations of the most abundant molecules to the least abundant ones.
- human blood proteins can differ in their concentrations by a factor of 10 9 (10 9 pg/ml for serum albumin compared with 0-5 pg/ml for interleukin 6).
- Analysis of a proteome may allow the identification of proteins useful as protein therapeutics, as biological targets for intervention via an interacting molecule, or as biomarkers for the characterization of tissue and diagnosis of disease.
- Biochemical markers for example, can be identified by analyzing tissue or body samples from a subject, preferably a mammal, with the disease of interest and then comparing the results of the analysis with those obtained from a subject without the disease.
- One successful approach using two-dimensional gel electrophoresis has led to the identification of a variety of marker proteins that are present at a significantly different concentration in tissue or body fluid samples of a diseased mammal relative to a normal mammal. See, for example, Partin et al. (1993) Cancer Res. 53:744-746 which describes the identification of prostate cancer markers and Getzenberg et al. (1996) Cancer Res. 5 6:1690-1694, which describes the identification of bladder cancer markers.
- Two-dimensional polyacrylamide-gel electrophoresis (2D PAGE) followed by mass spectrometry (MS) is the most widely used method of protein resolution and identification.
- 2D PAGE proteins are separated in one dimension by isoelectric point (pi) and in the other dimension by apparent molecular weight.
- pi isoelectric point
- 2D-PAGE has significant disadvantages. Firstly, each spot from 2D-PAGE must be individually extracted, digested and analyzed which is cumbersome, although limited robotic means have recently been developed to help automate this process.
- 20- PAGE also has a limited loading capacity and limited detection limit for staining, which, due to the large dynamic range of protein abundance in biological samples, results in an inability to analyze a complete proteome.
- Two-dimensional gel electrophoresis and tandem mass spectrometry typically have a dynamic range of only 10 2 to 10 4 .
- non-PAGE means have included ID chromatography and MS.
- CIEF and electrospray ionization (ESI) MS have been investigated (Tang et al, (1997) Anal. Chem. 69: 3177-3182).
- Tang et al resolved very few peptides electrophoretically.
- Two-dimensional chromatographic methods linked to MS or MS-MS have been developed as well.
- Several examples of systems for protein identification using peptide mapping have been described. In one example, Raida et al ((1999) J. Am. Soc. Mass Spectr.
- Opiteck et al coupled size exclusion and reverse phase HPLC (Opiteck et al, (1998) Anal. Biochem. 258: 349-361).
- Opiteck et al only a low number of proteins were identified from E. coli lysates.
- E. coli proteins were fractionated by anion exchange HPLC and portions were digested with trypsin and processed on a reverse phase microcolumn HPLC (Link et al, (1997) Int. J. Mass. Spectrom. Ion Proc. 160: 303-316).
- a mixture from Saccharomyces cerevisiae ribosomes was loaded onto reverse phase and eluted onto a cation exchange column from which peptides were separated and sprayed into an ESI tandem mass spectrometer (Tong et al, (1999) Anal. Chem. 71 : 2270-2278).
- the present inventors have achieved a separation of the biomolecules in a biological sample using novel means allowing the analysis of proteins present at low concentrations.
- Endocrine factors e.g., growth factors and hormones
- active peptides e.g., proteolytic products and post- translationally modified protein species
- These polypeptides clearly play a role in, and thus are valuable indicators of, the health of an individual.
- these polypeptides are generally small and easy to synthesize.
- the invention provides methods for complete fractionation of a biological sample, as opposed to traditional methods focused on purification of a particular protein or set of proteins.
- the methods involve separating proteins from a fluid sample by size exclusion chromatography into a limited number of fractions, preferably 10, more preferably 5, even more preferably 2 fractions, and then further separating small proteins using other chromatographic means.
- the chromatographic separation protocol is adapted for the separation or fractionation of protein fractions containing substantially intact (e.g. undigested) proteins and peptides, devoid of large proteins, and having reduced content of one or more high-abundance proteins. This provides a sensitive and comprehensive means for detecting low abundance proteins. Larger proteins are separated and analyzed in parallel with the help of electrophoretic means if desired.
- the methods of the invention unlike currently available methods such as 2D PAGE, are scalable. Thus, a wide range of different sample volume can be used, including large (e.g. at least several liters) quantities of biological samples such as plasma.
- the invention features methods of separating, identifying and/or analyzing proteins of a sample wherein a size exclusion column is used to select small proteins, . e. proteins with a molecular weight below a preset cutoff of, e.g., 30kD, 20kD, or 15kD.
- a size exclusion column is used to select small proteins, . e. proteins with a molecular weight below a preset cutoff of, e.g., 30kD, 20kD, or 15kD.
- the methods can be exemplified in a number of embodiments.
- One embodiment is a method of separation, detection or analysis of proteins of a sample which includes: - introducing a sample to a size exclusion column comprising an input and an output end, wherein the size exclusion column separates proteins of the sample and retaining the proteins of less than 30kD, less than 15kD, most preferably less than 20kD in a limited number of output fractions (preferably 10, more preferably 5, still more preferably 2, even more preferably 1); and introducing said retained output fractions from said size exclusion column to at least one further chromatographic column which separates proteins according to one or more additional physical property(ies) wherein said at least one further chromatographic column produces an effluent stream of eluted components (first or more dimension(s) of separation).
- improved sensitivity is achieved when using the system of the invention by incorporating a step to remove one or more of the most abundant proteins from the biological sample.
- Reducing the content of a protein in a sample can also be referred to as 'depleting' the sample of a protein.
- a biological sample comprising a target protein is introduced to a functionalized support, preferably an affinity column, including input and output ends and a target-specific adsorbing means, wherein the functionalized support selectively retains the target protein from the sample to produce an effluent stream having reduced concentration, or substantially lacking, the target protein.
- the method comprises: introducing a sample to one or more affinity chromatography column(s), each of them functionalized with a ligand capable of selectively or specifically binding one abundant protein in the sample, wherein the affinity column(s) produce(s) or output(s) a sample having a reduced content in at least one abundant protein; introducing said sample having a reduced content in at least one abundant protein to a size exclusion column comprising an input and an output end, wherein the size exclusion column separates proteins of the depleted sample and retaining the proteins of less than 30kD, less than 15kD, most preferably less than 20kD in a limited number of output fractions (preferably 10, more preferably 5, still more preferably 2, even more preferably 1); and introducing said retained output fractions from said size exclusion column to at least one further chromatographic column which separates proteins according to one or more additional physical property(ies), wherein said at least one further chromatographic column produces an effluent stream of eluted components (first or more dimension(s)
- preferred examples for said further column(s) include passage over ion exchange and/or reverse phase HPLC columns, most preferably an ion (cation) exchange followed by reverse phase HPLC.
- first further column separates components to produce a first effluent stream which is split in a number of fractions (first dimension of separation), and then the fractions are individually introduced to the second further column to produce a second effluent stream (second dimension of separation).
- the method comprises: - introducing a sample to one or more affinity chromatography column(s), each of them functionalized with a ligand capable of selectively or specifically binding one abundant protein in the sample, wherein the affinity column(s) produce(s) or output(s) a sample having a reduced content of at least one abundant protein; introducing said sample having a reduced content of at least one abundant protein to a size exclusion column comprising an input and an output end, wherein the size exclusion column separates proteins of the depleted sample and retaining the proteins of less than 30kD, less than
- all the output fractions from said size exclusion column which comprise, or are enriched in, proteins of less than 30kD, less than 15kD, most preferably less than 20kD, are introduced to a further chromatography column. Treating the complete set of proteins under the molecular weight cutoff provides a more complete inventory of low molecular weight proteins from a proteome.
- the components introduced to said affinity column, said size exclusion column, said further column(s), said ion exchange column and/or said reverse phase column are substantially intact proteins. That is, said proteins have not been subjected to a digestion step. Most preferably, in addition, the biological sample has been maintained so as to prevent unwanted degradation or digestion of proteins.
- the method comprises concentrating the components eluted from the size exclusion column.
- the methods thus include introducing retained fractions from said size exclusion column, which comprise, or are enriched in, proteins of less than 30kD, less than 15kD, most preferably less than 20kD, to a means for increasing the. concentration of proteins in solution.
- said means is a reverse phase capture column.
- the methods further comprise: directly detecting the mass of a plurality of the proteins of less than 20kD eluted from one of said chromatographic column, preferably using mass spectrometry.
- the methods of the invention are carried out on a biological sample from individuals displaying a detectable trait, for example a disease of interest, and repeated for a biological sample obtained from individuals not displaying a detectable trait, to be used as a reference sample.
- the invention thus features a system and methods for the rapid and efficient separation of proteins and other biological macromolecules.
- the invention provides a means for total analysis of a protein-containing sample comprising a means for specifically removing abundant proteins, a means for separating lower and higher molecular weight proteins, and at least one chromatography column for fractionation of lower molecular weight proteins and peptides.
- the system also comprises a gel electrophoresis means for separation and recovery of higher molecular weight proteins.
- the system further comprises a mass spectrometer or an array of mass spectrometers and an analysis means for identification of peptides and proteins from mass spectrometric data.
- a system including a sample input means, a size exclusion separation device for separating proteins in a limited number of outputs fractions (preferably 10, more preferably 5, even more preferably 2); at least one liquid chromatography column for separating proteins according to an additional physical property.
- the column for separating proteins according to an additional physical property is operative successively with the size exclusion separation device.
- the system further provides a means for the selective, or more preferably specific, removal of one or more abundant proteins before the size exclusion separation.
- the system further comprises at least a size exclusion separation device and at least two further chromatography columns adapted to separate proteins according to a distinct dimension.
- said further columns comprise an ion exchange column and a reverse phase HPLC column.
- said further columns comprise an ion exchange column and two reverse phase HPLC columns, in order to separate the proteins according to 3 dimensions.
- the various means and steps for separation of proteins in a sample and/or elimination of abundant proteins can be arranged in any suitable order. However, preferred arrangements are further disclosed below.
- the preferred system comprises: a sample input means; one or more solid support, preferably comprised in an affinity chromatography column, said support functionalized with a ligand capable of binding an abundant protein in biological fluids; a size exclusion chromatography column; and at least one further liquid chromatography column.
- the system typically also comprises an injection valve connecting the sample input means to the first column of the system, and one or more pump means for providing pressure delivery of a solution to the column(s).
- the pressure is provided via a valve (preferably a multiport valve).
- the system preferably also comprises a program means for specifying system control programs.
- the apparatus further includes control means in communication with the pump means for controlling the pressure of delivery of the solution.
- One or more of the columns can be operably linked, such that eluant from one column can be directly passed to a subsequent column, thereby also allowing at least a portion of the steps to be automated or carried out 'inline'.
- operably linked columns comprise a valve for removing at least a portion of the eluate, for example, for the purpose of storage.
- the system may also comprise solution input means including plural solution reservoirs, and a mixing valve, connecting the solution input means to a sample input means connected to a column, operative to mix solution from the reservoir, wherein program means specifies the mixing of solution by the mixing valve, and the delivery of the mixed solution to the column via a multiport injection valve.
- solution input means including plural solution reservoirs, and a mixing valve, connecting the solution input means to a sample input means connected to a column, operative to mix solution from the reservoir, wherein program means specifies the mixing of solution by the mixing valve, and the delivery of the mixed solution to the column via a multiport injection valve.
- the system generally also includes at least one detector means for detecting and recording column output.
- at least one detector means for detecting and recording column output.
- the invention features a system for the separation of proteins, which includes a plurality of chromatography columns according to the invention, means for introducing a solution into a first said column, multiple multi-port valves in communication with said columns through which solution is transported, and output means comprising a detector and data collector.
- this embodiment includes pump means for introducing solution, preferably a complex biological fluid such as plasma, into the first column; control means in communication with the pump means for controlling the pressure of delivery of the solvent.
- solution preferably a complex biological fluid such as plasma
- control means in communication with the pump means for controlling the pressure of delivery of the solvent.
- fractions or samples eluting from one column or support can be further processed inline or can be manually introduced to a further column.
- fractions or samples can be aliquoted and/or pooled (e.g., from multiple, repetitive runs) and/or stored after eluting from any column, e.g. for use in another protocol, such as 2-dimensional gel electrophoresis.
- the multiple valves include first, second, and third valves, and the solution is introduced through the first valve into the first column, through the second valve into the second column, and through the third valve to a third column, or to an output means.
- the valves are preferably multi-port valves.
- the solution introducing means comprises sample input means which includes a sample reservoir.
- the sample input means may further include a sample pump, and the solution introducing means may include plural solution reservoirs, a valve for selection and mixing solutions, and a pump for delivering solution to the first column.
- the output means may further include a fourth multi-port valve connecting the detector to the data collector.
- the detector may be a UV detector.
- the output means may further include a pH/conductivity detector in communication with the detector and the data collector through the fourth multi-port valve.
- the column has a first and a second end and at least one of the first or second columns is packed with a chromatography matrix which confers on the packed column a desired transit time and a separation according to a desired physical property of proteins.
- the system of the invention (e.g. the plurality of columns and supports and the arrangement thereof) is adapted for the separation of undigested lower molecular weight proteins, preferably under 30kD, more preferably under 15kD or most preferably under 20kD.
- a so-adapted system comprises a column functionalized with ligands specific for at least one abundant protein (for example an abundant plasma protein), a size exclusion means to select for lower molecular weight proteins, and at least one or preferably at least two further chromatography columns, each of said further columns packed with a particulate matrix separation medium for separation according to a distinct protocol with the use of according elution media and conditions.
- the system also comprises a means for concentrating samples eluting from the size exclusion means; in a preferred aspect a reverse phase capture column is used.
- the system also includes a sample input means including an input valve for delivery of solutions to one of said further columns at the column input end and a multiport valve for mixing solutions provided to the input valve, column output means for detecting column output including means for detection and providing a signal indicative thereof, and control means for operating the sample input means.
- the control means may include a means for alternatively utilizing one of the chromatography columns or another, for example, or for delivering different media to different columns, or for directing the processing of fractions obtained from a first fractionation protocol.
- the apparatus may thus include program means for specifying a sequence of separation process control programs to be successively run during operation.
- the program means may specify a separation program in which a first and a second column are utilized successively for separating proteins in the sample, or a separating program where multiple fractions of a sample are delivered to a column (e.g. multiple runs), or a pooling program where a plurality of fractions are to be combined in a pooled fraction.
- one of the said further columns of the system includes an ion exchange chromatography matrix, most preferably a cation exchange matrix.
- one of the said further columns of the system column may include a reverse phase chromatography matrix, preferably for use in reverse phase HPLC.
- Each of the further columns (e.g. at least a first and a second further column) individually, may be removable and replaceable.
- the system of the invention may involve arranging columns so that they are operably connected. Nevertheless, in several preferred embodiments of the invention, samples and fractions will need to be processed according to more than one method or specific protocol. For example, at some stages as described further below, it will be preferable to remove a portion of a sample or fractions for storage.
- a separation step may have output fractions of proteins that are optimally further processed according to differing protocols.
- columns may not be operably connected, or alternatively, more complex connections or manipulations are provided with the aid of multiport valves and a process control program.
- a monitoring device can be provided.
- a sample can be arranged to flow through a detector, thereby resulting in a graph with peaks for proteins and other non -target solutes, from which a measure of the purity and concentration of the proteins can be derived.
- Advantages of this embodiment of the invention include rapid monitoring of the presence, quantity, and/or purity of proteins in a fraction derived from a complex biological sample such as plasma. Impurities may also be monitored - such as certain abundant proteins, nucleic acids, endotoxins, or generally any biological molecule detectable in the sample.
- the methods and apparatus of the invention are rapid, reliable, and adaptable, and are particularly useful in the separation and purification of proteins, particularly in the context of identifying a large number of proteins from a biological sample by fluid separation. Further details and examples are provided below.
- Figure 1 is a flow diagram depicting one implementation of the methods of the invention.
- Figure 2 is a flow diagram depicting one implementation of the methods of the invention. More precisely, steps 5 to 6 of Example 1 are illustrated.
- Figure 3 illustrates the MALDI-MS spectra obtained from the protein Leptin using the methods of the invention, as described in Example 2.
- Figure 4 illustrates the MS/MS spectra obtained from the protein Leptin using the methods of the invention, as described in Example 2.
- Figure 5 illustrates the sequence coverage obtained from the protein Leptin by mass spectrometry using the methods of the invention, as described in Example 2.
- polypeptide refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-translational modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl, acetyl, phosphate, amide, lipid, carboxyl, acyl, or carbohydrate groups are expressly encompassed by the term polypeptide.
- polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc ), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring
- amino acid including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc
- polypeptides with substituted linkages as well as other modifications known in the art, both naturally occurring and non-naturally occurring
- protein as used herein may be used synonymously with the term
- polypeptide or may refer to, in addition, a complex of two or more polypeptides which may be linked by bonds other than peptide bonds, for example, such polypeptides making up the protein may be linked by disulfide bonds
- protein may also comprehend a family of polypeptides having identical ammo acid sequences but different post-translational modifications, particularly as may be added when such pioteins are expressed in eukaryotic hosts
- protein fractionation refers to an analytical technique used to separate molecules Several of the methods of fractionation well-known to those of skill in the art include chromatography, electrophoresis, and isoelectric focusing
- sample and “biological sample” are used interchangeably, and include material derived from an animal, preferably a mammal, more preferably a human
- a sample is a liquid sample derived from a human or animal
- Such liquid samples include but are not limited to blood, plasma, serum, serum derivatives, bile, phlegm, saliva, tears, ammotic fluid, urine, peritoneal fluid, lymph, vaginal secretion, semen, spinal fluid, ascitic fluid, saliva, sputum, breast exudate, synovial fluid and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF
- CSF cerebrospinal fluid
- detectable trait refers to any visible, detectable or otherwise measurable property of an orgamsm
- detectable trait refers to symptoms of. or susceptibility to, a disease, or to refer to an individual's response to an agent, drug, or treatment acting on a disease, or to refer to symptoms of, or susceptibility to, side effects to an agent acting on a disease
- fraction refers to part of a sample which has been split in a number of sub-samples of significantly differing compositions, typically as obtained after a chromatography step
- aliquot and portion refers to part of a sample which has been split in a number of sub-samples of equivalent compositions, in particular containing similar proteins in similai quantities
- Samples can be aliquoted at any stage in the methods of the invention, e g to prevent overloading a column when processing the sample by conducting multiple runs on aliquots is preferred. Similar fractions resulting from multiple runs may be pooled together at any stage in the methods of the invention. It will therefore be apparent to one skilled in the art that aliquot, or portion, as used herein, may represent any volume of sample, and is not limited to small sample volumes.
- the method can be used to identify markers, targets, or protein therapeutics in tissue or body fluid samples.
- the method is particularly useful for the analysis of a body fluid, for example, blood, plasma, serum, serum derivatives, bile, phlegm, saliva, sweat, tears, amniotic fluid, urine, peritoneal fluid, lymph, vaginal secretion, semen, spinal fluid, ascitic fluid, saliva, sputum, breast exudate, synovial fluid and cerebrospinal fluid (CSF), such as lumbar or ventricular CSF.
- Plasma is most preferred.
- the plasma samples are preferably maintained such that protein quality is not compromised.
- Conventional means of storing plasma samples can be used, such as addition of protease inhibitors, and anti-coagulants.
- the sample is obtained and stored using known methods for maintaining a sample.
- anticoagulant and antiprotease compositions are added to the blood or plasma samples.
- blood cell activation, aggregation and adhesion inhibitors are added.
- Commonly used anticoagulants fall into two general classes, the thrombin inhibitors and the calcium chelators. Of the thrombin inhibitors, heparin is the most commonly used today.
- antiproteases include serine protease inhibitors (e.g., reversible and irreversible thrombin inactivators, Xa factors), inhibitors of cysteine proteases, calpain proteases and metalloproteases.
- Blood cell activation, aggregation and adhesion inhibitors include for example platelet activation inhibitors, platelet-platelet interaction inhibitors, phospholipid-binding inhibitors, and fibrinogen inhibitors.
- the anticoagulation and antiprotease mechanisms are selected so as not to interfere ⁇ vith methods for detecting proteins in the biological sample.
- a blood sample will be introduced into a means for receiving blood, such as a syringe or capsule, which has blood contacting surfaces that are coated with anticoagulant compositions
- Anticoagulants as well as antiprotease compounds can also be added to the blood or plasma sample itself
- a combination of anticoagulants and/or antiprotease compounds are used
- mixtures generally comprise at least two se ⁇ ne protease inhibitors in addition to the blood coagulation-retardant compounds, and in the case of blood also blood cell activation, aggregation and adhesion inhibitors
- the methods of the invention are particularly advantageous since they can be used in connection with a wide range of scientific protocols, particularly using widely varying amounts of fluid sample
- separation is carried out at an industrial scale on a large quantity of sample, thereby providing highest sensitivity for the detection of rare proteins and peptides
- the protein component optionally excluding specifically removed proteins depending on the particular method used, from at least 100 mL, 500ml, IL, 2L, 10L, 20L, 25L of biological sample (for example blood, plasma, serum,date, etc ) is introduced to a size exclusion chromatography column
- a large volume of sample (2 5L in the case of Example 1) can be divided into a plurality of ahquots and introduced to the column separately so that a plurality of runs are carried out If desired, the components eluted
- the invention can be used in the separation and analysis of proteins and peptides using smaller volumes This is more applicable in situations where less fluid sample is available such as in the case of CSF for example, or less sensitivity is required
- at least 1 mL, 5mL, lOmL or 50mL of fluid sample are processed using the methods of the invention
- a sample is obtained from a single individual
- a proteomics study may involve detecting proteins present in a sample from an individual displaying a given trait and an individual not displaying said trait Preferably the individuals will be matched for factors other than said trait. Any number of individuals can be used in a study.
- the methods according to the invention e.g. separation or fractionation of proteins, and detection
- the sample will generally be a pooled sample that combines samples from a number of individuals. This method also allows comparison between samples from trait-displaying individuals and reference individuals, thereby resulting in an averaging of the levels for the proteins present in each pooled sample.
- a pooled biological sample contains biological fluid from at least 2, 5, 10, 20, 50, 75 or 100 individuals.
- an exemplary pooled plasma sample may comprise at least 10 mL, or preferably at least 50 mL of plasma from each of at least 50 individuals.
- a quantity of pooled sample to be processed according to the methods of the invention may be provided as a single sample, or may be divided into a plurality of samples.
- a sample may be divided into a plurality of substantially identical smaller samples, herein described as "aliquots" or "portions". This permits large volumes of biological samples to be treated without overloading a separation column.
- a series of sample runs can be combined after a separation step by combining analogous fractions.
- analogous fractions are combined following the separation step, that is, without subjecting the fractions to a further separation step.
- fractions obtained following a separation step are subjected to one of further chromatographic separation steps, and only then are analogous fractions combined.
- the fractions that are combined can ultimately be analyzed using mass spectrometry techniques, increasing the ability of the analysis system of the invention to detect proteins present in plasma in low abundance. Further details and examples for aliquoting, and combining or pooling following separation steps are further provided below.
- Chromatographic techniques are well known in the art as means for separating components (solutes) present in a mixture. These techniques are particularly useful in the chemical and biotechnological arts.
- True chromatography describes the separation of solutes according to their different partitioning between two (or three) phases.
- the phases generally are solid and liquid, and solute partitioning results in their differing mobilities through a layer of solid, typically particulate, matrix in the presence of a flowing phase. Solute transfer through the layer may be along a pressure gradient, generally referred to as "liquid chromatography".
- Chromatographic matrices can separate components by any of a number of criteria, including size, electrical charge, hydrophobic interaction, and/or specific affinity for the matrix or binding sites thereon. Because the components in the mixture will vary in their affinity for the matrix, their partitioning as they pass through the matrix separates the components so that they exit the matrix sequentially, separated temporally and spatially.
- Determination of the location of the various separated components, or of a given component of interest within the sequence generally is achieved by collecting the fluid phase exiting the matrix (i.e., the effluent stream) as a series of fractions and sampling these fractions to identify their contents by any of a number of means known in the art.
- removal of abundant proteins provides improved sensitivity for the detection of low- abundance proteins.
- means are used which remove known abundant proteins, thereby minimizing the undesired removal of proteins to be identified according to the methods of the invention.
- One or a plurality of abundant proteins or class of abundant proteins may be removed.
- Preferred methods use affinity chromatography, although it will be appreciated that the invention is not limited thereto, and any suitable non-chromatographic means can be used to remove abundant proteins.
- albumin makes up more than 50% of the total human serum protein content by weight (Putnam, R.W., The Plasma Proteins, Academic Press, New York 1975).
- immunoglobulin (Ig) light and heavy chains present at high concentrations in plasma.
- the presence of the abundant albumin and Ig impedes effective resolution and detection of many low abundance proteins.
- human serum albumin and/or immunoglobulins are specifically removed.
- abundant proteins making up at least 5%, 10%, 25%, 50%, 60%, or 75% (w/w) of the total protein mass of a liquid sample are removed using means for the specific removal of abundant proteins.
- main proteins that can be removed from plasma are haptoglobin and transferin.
- Immunoglobulins and/or albumin proteins can be extracted using any suitable conventional methodologies used in the art.
- affinity-based methodologies are used.
- immunoglobulin can be removed selectively from samples using binding proteins, for example, an antibody or a fragment thereof, Protein A, or Protein G, immobilized on a solid support.
- a solution of interest can be passed through a chromatography column packed with such a solid support under conditions such that the immunoglobulin molecules preferentially bind to the matrix.
- the resulting column flow through therefore, is depleted of immunoglobulin.
- Similar methods can be used with albumin ligand to remove serum albumin.
- a fluid sample comprising substantially undigested proteins and peptides, e.g. which has not been substantially subjected to any digestion process.
- the fluid sample has preferably not been subjected to any filtration procedure that would remove a substantial number of proteins or peptides having a molecular weight of less than about 20kDa from the sample. Referring to FIG 1, the sample is injected onto two inline affinity chromatography columns, one column comprising an albumin ligand and a second column comprising Protein G, shown in step 101.
- the non-retained fraction can then be processed further immediately according to the invention, such as by collecting fractions and injecting to another column (e.g. size exclusion) or by processing on-line on a further column.
- the non-retained fraction, or a portion thereof can be frozen and stored for further processing at a later time.
- the sample is divided into several aliquots and multiple runs can be performed, such as 20 runs as shown in FIG 1.
- Non-retained fractions from multiple runs can either be pooled, or can be processed further individually. In a preferred example in FIG 1, fractions are frozen and stored individually and then injected onto a size exclusion column.
- albumin can be removed selectively for samples of interest via affinity chromatography, using, for example, Sepharose coupled to Cibacron blue available commercially from Pharmacia and Upjohn, Peapack, NJ, or using an albumin ligand, available commercially from Amersham, Upsala, Sweden.
- albumin and immunoglobulin G can be removed simultaneously from serum using techniques such as those described in Lollo et al ((1999) Electrophoresis 20:854-859). In most preferred methods, abundant proteins are removed using highly specific ligands.
- ligands examples are provided in International Patent Publication No. WO 00/37501, the disclosure of which is incorporated herein by reference. Although removal of serum albumin using Cibacron-blue can be used, more preferred methods use specific ligands that remove substantially only the protein of interest. Cibacron-blue dye binds many proteins other than albumin, such as interferon, lipoproteins, blood coagulation factors, kinases, dehydrogenases and most enzymes requiring adenyl-containing cofactors. On the other hand, a specific ligand typically exhibits an affinity between the reagent and the specific protein to be removed of at least about 10 6 M Ka.
- Specific ligands may be generated de novo against proteins to be removed or selected from libraries of ligands.
- specific ligands include antibodies (e.g., polyclonals from animals, monoclonals from hybridomas), single chain antibodies from phage display libraries (Vaughan et al., Nat Biotechnol. 1996, 14:309-14), small peptides (Norman et al. Science 1999, 285:591-5) or RNA-protein fusion libraries (Kreider et al. MedRes Rev 2000, 20:212-5), DNA and RNA aptamers (Kusser et a/. JBiotechnol, 2000.
- a liquid sample is depleted from abundant proteins by contacting the sample with a polypeptide affinity reagent.
- polypeptide affinity reagent refers to a polypeptide that specifically binds to a macromolecule of interest in a liquid sample to be depleted.
- Specifically binds means the adsorptive polypeptide recognizes and binds a specified macromolecule, but does not substantially recognize and bind other molecules in a sample, e.g., a liquid biological sample, that naturally includes a variety of macromolecules. The principle is to contact the liquid sample with reagents having specific affinity for a particular component or defined class of components. These reagents have narrow specificities for particular sets of macromolecules.
- Antibodies represent the main class of polypeptide affinity reagents that are immunoreactive or bind to epitopes of macromolecules.
- epitope refers to any antigenic determinant on an antigen to which an antibody binds. Epitopes usually are chemically active surface groupings of amino acids or sugar side chains and usually have specific three- dimensional structural characteristics, as well as specific charge characteristics.
- antibody includes intact antibody molecules as well as fragments thereof, such as Fab, Fab 1 , Fv, and single chain antibody that can bind the epitope. These antibody fragments retain some selective ability to bind the corresponding antigen or receptor. Particularly useful antibodies include polyclonal and monoclonal antibodies, chimeric antibodies, single chain antibodies and the like, having the ability to bind with high immunospecificity to abundant macromolecules.
- polyclonal antibodies The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green et al. ("Production of Polyclonal Antisera", in Immunochemical Protocols, Manson, ed., Humana Press, 1992, pages 1-5) and Colligan et al. (Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters, in: Current Protocols in Immunology, section 2 1, 1992), incorporated herein by reference. The preparation of monoclonal antibodies likewise is conventional. Monoclonal antibodies can be produced using methods well known in the art. See, Kohler et al.
- monoclonal antibodies can be obtained by injecting mice with an antigenic composition, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures.
- Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with protein-A Sepharose, size-exclusion chromatography, and ion- exchange chromatography.
- Multiplication in vitro may be carried out in suitable culture-media such as Dulbecco's Modified Eagle Medium (DMEM) or R.PMI 1640 medium, optionally replenished by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages.
- DMEM Dulbecco's Modified Eagle Medium
- R.PMI 1640 medium optionally replenished by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages.
- Production in vitro provides relatively pure antibody preparations and allows scale- up to yield large amounts of the desired antibodies.
- Large scale hybridoma cultivation can be carried out by homogenous suspension culture in an airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture.
- Multiplication in vivo may be carried out by injecting cell clones into mammals histocompatible with the parent cells, e.g., syngeneic mice, to cause growth of antibody producing tumors.
- the animals are primed with a hydrocarbon, especially oils such as pristane (2,6,10,14-tetramethyl-pentadecane) prior to injection. After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.
- polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
- a purified antibody may be obtained, for example, by affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.
- affinity chromatography using recombinantly-produced protein or conserved motif peptides and standard techniques.
- albumin-specific monoclonal antibodies refers to monoclonal antibodies that specifically bind to serum albumin.
- Specifically binds to albumin means the monoclonal antibody recognizes and binds to serum albumin, but does not substantially recognize and bind other molecules in a sample, e.g., serum or plasma, that naturally includes serum albumin.
- the invention provides a monoclonal antibody that can immunoprecipitate serum albumin from serum or plasma. This means that the monoclonal antibody recognizes an epitope on the albumin molecule that is not blocked by the numerous plasma and serum proteins that bind to albumin in serum or plasma.
- polyclonal antibodies provide specificity, there is the inherent variability in antibody population that occurs during separate immunization schedules that can lead to reproducibility problems. Additionally, the supply of polyclonal antibody containing serum is limited by the health and finite lifespan of the producing animal. Considering the large quantities of antibody required for the treatment of plasma, the use of polyclonal antibodies is possible but not preferred.
- Preferred ligands for the removal of abundant proteins include non-antibody peptide and protein ligands. Various commercially available peptide or protein ligands can be used. It will be appreciated that peptide ligands may also be prepared using known methods for generating and testing combinatorial peptide libraries.
- polypeptide affinity reagents examples include protein A and protein G.
- Protein A is a protein of MW 42,000 from the bacterium Staphylococcus aureus that binds to IgG from a wide range of species, including human, rabbit, donkey, pig, and guinea-pig. Protein A is commonly used as a secondary reagent in immunological and biological techniques, as described by Goding (J. Immunol Meth. 20: 241-253, 1978), and is available from Scripps Laboratories.
- Protein G is a monomeric protein (MW 63,000) from human group G streptococcus. Protein G possesses two or three antibody -binding sites and binds IgG from a wide range of species. Compared to protein A, protein G binds with a higher affinity to rat, mouse and goat IgG, as described by Bjrk et al. (J. Immunol 133, 969-974, 1984).
- a macromolecule-polypeptide affinity reagent complex is formed, that is then contacted with the other member of a high affinity binding pair system to form a "collapsible affinity matrix" (as described in PCT patent publication No. WO 99/39204).
- the collapsible affinity matrix is specific for the abundant macromolecule and, when centrifuged, contains very little dead volume that would-otherwise trap additional sample macromolecules.
- biotinylated adsorptive proteins can be used in such a method.
- a biotinylated anti-Human Serum Albumin (HS A) antibody in conjunction with avidin and human serum, forms a collapsible affinity matrix, containing albumin.
- biotinylated protein A avidin
- human plasma followed by contact with biotinylated anti-HSA and avidin allows simultaneous co-precipitation of albumin and immunoglobulin (Ig).
- the practice of the method of the invention can thereby provide plasma samples substantially depleted of albumin and immunoglobulin.
- Methods for removal of specific abundant proteins can be carried out one or a plurality of times on a single liquid sample to remove multiple abundant molecules.
- the invention thus preferably includes preparing a liquid sample according to the invention for fractionation by contacting the liquid sample with an affinity reagent having specificity for an abundant macromolecule in the sample.
- macromolecules include polynucleotides, polypeptides, and polysaccharides. Examples also include glycoproteins, in which saccharide (sugar) moieties are covalently bound to polypeptides, and nucleoproteins, which are complexes of polynucleotide and polypeptide.
- An "abundant macromolecule” or an “abundant protein” is respectively a macromolecule or protein present in a sample in such quantity that the presence of the macromolecule or protein interferes with an aspect of the analysis of the sample.
- An abundant macromolecule or protein may constitute for example at least about 1%, 5%, 10%, 25% or 50% of the total protein in a sample.
- a plasma or serum sample is obtained that is substantially depleted in albumin and immunoglobulins.
- substantially depleted means that the most abundant proteins have been removed such that the plasma or serum sample contains less than 50% (w/w) of the total proteins before depletion. Size exclusion of intact proteins and peptides
- the fluid sample is subjected to at least one size-exclusion separation or fractionation step.
- size-exclusion separation or fractionation step other methods such as ultrafiltration methods can be used, use of size-exclusion liquid chromatography is preferable due to advantages, e.g. in protein recovery yield.
- the present invention provides a system for analyzing the biomolecules present in a biological sample, typically the proteins and peptides present in a "proteome", it will be appreciated that the samples to be injected to the size exclusion column are not pre-treated in such a way as to remove a substantial number of proteins to be identified.
- a sample will generally not be subjected to a treatment which would substantially reduce the diversity of the protein or peptide complement of the sample to be analyzed according to the methods of the invention, or which would non-specifically remove proteins or peptides from the sample based on criteria other than size.
- a plasma sample will preferably not be subjected to a conventional ultrafiltration step which is known to non-specifically remove proteins which may stick to the ultrafiltration membrane.
- the sample may be aliquoted so long as substantially all protein-containing aliquots obtained thereby are subsequently included in the size-exclusion separation step.
- the biological sample will not have been treated so as to cause the digestion of a substantial number or amount of proteins and peptides in the sample.
- the sample has not been treated by the addition of trypsin or other proteolytic enzyme prior to the size exclusion step.
- non-retained fractions stored following affinity chromatography for the removal of abundant proteins are injected onto two inline gel filtration columns (103). Each fraction from affinity chromatography step (101) is injected separately to the gel filtration columns (103) resulting in a total of 20 runs. The second of the gel filtration columns is connected inline to a reverse phase capture column, as further discussed below. Eluted fractions enriched in small (e.g., 20kD or lower) proteins and peptides can be retained for further processing.
- the size exclusion step can be a preparative step, which means that it is used solely to remove large proteins from the sample and not to resolve the complexity of the proteins contained in the sample by, e.g. fractionating the sample into a large number of fractions which would be all individually further processed by the methods of the invention.
- all the output fractions from said size exclusion column which comprise, or are enriched in, proteins of less than 20kD are introduced to a further chromatography column.
- Treating the complete set of proteins under the molecular weight cutoff provides a more complete inventory of low molecular weight proteins from a proteome.
- "retaining the proteins of less than 20kD” means retaining substantially all proteins from the sample which have a molecular weight below 20kD, with the understanding that this may be somewhat limited by technical constraints.
- more than 80%, preferably more than 85 %, even more preferably more than 90 %, even more preferably more than 95 %, even more preferably more than 98 %, still more preferably more than 99 % of the proteins of less than 20kD contained in the initial sample are retained by the size exclusion step and processed further by the methods of the invention.
- Size exclusion chromatography also known as gel permeation or gel filtration chromatography, does not involve any adsorption and has the advantage of being fast.
- the packing is a porous gel, and is capable of separating large molecules from smaller ones. The larger molecules elute first since they cannot penetrate the pores. This method is common in protein separation and purification processes.
- At least 1 mL, 5 mL, 10 mL, 50 mL, 100 mL, 200mL, 500 mL, 750 mL, 1 L, 2 L, 5 L or 10 L of fluid sample comprising substantially intact and undigested proteins will be subjected to the size-exclusion based separation or fractionation step. It will be appreciated that where said sample has already been separated into multiple aliquots, the aliquots can be passed over the gel filtration column during the course of a plurality of runs.
- any suitable filtration device, medium and conditions can be used in accordance with this aspect of the invention.
- the sample can be injected to the gel filtration column(s) in a series of aliquots.
- the gel filtration column has a volume of at least 10 mL, 100 mL, 200 mL, 300mL, 400 mL, 500 mL, 750 mL, 1 L, 2 L, 5 L or 10 L of fluid sample.
- two in line columns may be used.
- column volume is comprised between 10 and 40 liters, with column diameter comprised between 10 and 30 cm.
- the column size is defined according to the sample volume so that the sample volume does not exceed 5% of column volume.
- Linear velocity is comprised between 15 and 60 cm/h, depending on the media and apparatus used. A large range of media can be used; the fractionation range must ensure an adapted separation for the chosen molecular weight cutoff, e.g. 20 kDa.
- the protein and peptide samples are preferably concentrated
- a preferred method for concentrating proteins and peptides is to use a reverse phase capture column
- the reverse phase capture column(s) (103) can be advantageously connected inline to the gel filtration column
- multiple gel filtration aliquots are processed on the inline reverse phase capture columns, leading m turn to multiple reverse phase capture aliquots
- These fractions can then be stored or further processed individually or may be pooled according to any desired arrangement
- fractions obtained from a preceding inline gel filtration column are further processed on two mime reverse phase capture columns
- Eluted fractions are pooled and further split into 6 aliquots of about 200 mg of protein (105)
- the analysis of complex mixtures according to the invention preferably involves separation according to several dimensions in order to resolve all the components present in a sample It is for this reason that multi-dimensional separation schemes have been devised When constructing a successful multi-dimensional system several criteria need to be addressed In one aspect, the techniques should base their respective separations on widely variant criteria Doing so will reduce the amount of redundant information contained in the resulting dataset
- a biological sample is treated according to one or more separation protocols as described herein.
- substantially the entire protein content, and thus the protein diversity, or substantially all the retained protein-containing fractions from the size-exclusion step are subjected to further separation steps.
- the invention discloses a method for identification of proteins comprising a multidimensional liquid chromatography separation process. Following a size- exclusion-based step and optional concentration step(s), proteins and peptides are subjected to one or a plurality of liquid chromatographic separation or fractionation steps. This process is preferably carried out on protein fractions obtained from said size-exclusion step which are enriched in low molecular weight proteins, preferably proteins of less than 20kD.
- fractions enriched in proteins of lower molecular weight are subjected to liquid chromatography protocols as further described herein.
- liquid chromatography protocols are selected from the group consisting of ion exchange, reverse phase, affinity chromatography, Immobilized Metal Affinity Chromatography, Dye-Ligand affinity chromatography, Hydrophobic Interaction
- Ion (cation) exchange chromatography fractions obtained via size exclusion chromatography are subjected to ion (e.g. cation or anion) exchange chromatography, preferably cation exchange, followed by reverse phase HPLC.
- ion (e.g. cation or anion) exchange chromatography preferably cation exchange
- fractions enriched in proteins and peptides of 20kD or less are obtained from gel filtration and a subsequent concentration step, and are injected to a cation exchange column (106).
- multiple runs e.g. from individual aliquots following size exclusion
- cation exchange multiple runs (e.g. from individual aliquots following size exclusion) on cation exchange are carried out, such that a plurality of fractions are obtained for each run.
- 6 runs are carried out for the 6 aliquots obtained from reverse phase capture, each containing about 200 mg of protein, and each run resulting in about 20 fractions from cation exchange. Similar fractions from different runs are then pooled together.
- Ion exchange chromatography is commonly used in the purification of biological materials.
- ion exchange in which the stationary phase carries a negative charge
- anion exchange in which the stationary phase carries a positive charge.
- Charged molecules in the liquid phase pass through the column until a binding site in the stationary phase appears. The molecule will not elute from the column until a solution of varying pH or ionic strength is passed through it. Separation by this method is highly selective. Since the resins are fairly inexpensive and high capacities can be used, this method of separation is applied early in the overall process. The choice of pH must ensure quantitative adsorption of the proteins. The ionic strength of the buffer used must be low for the same reason.
- Chromatography with cation exchange media needs the use of acidic pH, compatible with biological fluid to prevent protein precipitation.
- Chromatography with anion exchange media needs the use of basic pH, at a value compatible with preservation of the peptide link.
- the column size is defined according the protein quantity to fractionate, determined after capacity studies.
- the column height preferably does not exceed 25 cm and the column diameter is deduced from capacity and column height according the following equation:
- the mobile phase is composed of two solutions.
- the first solution (A) is composed of an acidic buffer as further provided.
- the second solution (B) is composed of the same buffer as in A containing a high concentration of salt (e.g., NaCl IM).
- the column is equilibrated with 100 % of solution A, the protein sample is injected and the column is washed with solution A. Adsorbed proteins are progressively eluted and so resolved by a linear or step gradient from 0 % of B to 100% of B.
- the elution profile of a given polypeptide from cation exchange is linked to the number of positive charges.
- Eluted protein solution must be compatible with the following step, in one example reverse phase high performance liquid chromatography (RP-HPLC).
- RP-HPLC reverse phase high performance liquid chromatography
- fractions obtained from cation exchange may or may not be pooled, depending on the needs of the user.
- 6 runs are carried out on a cation exchange column, resulting in 20 fractions for each run. These 120 fractions are then reduced to 20 fractions by combining fractions from each of the 6 runs.
- Example 1 another pooling strategy is described. It will be appreciated that pooling of eluted fractions may be inter-run or intra-run, and fractions to be combined may be selected according to any suitable criteria. Preferably analogous samples from multiple runs are pooled.
- Reverse Phase HPLC fluid samples are fractionated on a reverse phase column (111 and/or 116).
- Reverse phase chromatography is a powerful analytical tool and involves a hydrophobic, low polarity stationary phase which is chemically bonded to an inert solid such as silica. The separation is essentially an extraction operation and is useful for separating nonvolatile components.
- both reverse phase chromatography and ion exchange chromatography may be used, in any order.
- the method of the invention combines ion exchange and reverse phase HPLC.
- samples are injected onto an ion exchange, preferably cation exchange, column (106), and subsequently fractions eluted therefrom are injected onto a reverse phase column (111).
- ion exchange chromatography 106
- eluted fractions may be reduced and alkylated (108) before injection to a reverse phase column (111).
- a reverse phase column (111) may be connected inline to the ion exchange column (106).
- eluted fractions from the ion exchange column are collected and fractions are pooled (107) prior to injection of the fractions to the reverse phase High Pressure Liquid Chromatography (HPLC) column (111).
- pooling (107) may be inter-run or intra- run, and fractions to be combined may be selected according to any suitable criteria.
- Reverse phase HPLC can be configured to produce a number of fractions as desired. In the exemplary protocol of Figure 1, 30 fractions are generated for each of the 20 fractions injected to the reverse phase column. Following reverse phase HPLC, fractions can be dried (115) for storage if desired.
- a system of the invention comprises a first and a second reverse phase HPLC columns.
- the second reverse phase column can be connected inline to said first column.
- the protein concentration of one or a plurality of fractions is adjusted; for example fractions having an abnormally high protein level are diluted or injected as multiple runs, based on optical density (OD) measurements (109, 110, 113 and 114). Aliquots injected as multiple runs may be pooled back together at any later stage (112).
- fractions can be dried (115) for storage if desired, and resuspended when a further fractionation (e.g. second reverse phase fractionation) is to be carried out. Fractions are then injected to a second reverse phase HPLC column (116).
- the second reverse phase HPLC step generates 24 further fractions.
- Reverse phase high performance liquid chromatography is similar to reverse phase, only in this method, the process is conducted at a high velocity and pressure drop.
- the column is shorter and has a small diameter, but it is equivalent to possessing a large number of equilibrium stages.
- This method is essentially characterized by the use of low diameter chromatography beads, typically from 3 ⁇ m to 20 ⁇ m.
- the column dimensions are chosen as for ion exchange chromatography.
- the mobile phase is composed of two solutions.
- the first (A) is composed of water acidified with trifluoroacetic acid for example (0.1% w/v).
- the second solution (B) is composed of solvent such as acetonitrile, containing a minor proportion of water (e.g. 20 %).
- Protocols to separate proteins can be used in addition to, or place of, the ion exchange- and/or reverse phase- based methods.
- a range of suitable multi-dimension protocols can thus be devised based in the present invention.
- Chromatography methods that may be used in such embodiments at some point in the separation process, preferably following the size exclusion step, include for example affinity chromatography, immobilized metal affinity chromatography, dye-ligand affinity chromatography, hydrophobic interaction chromatography, hydroxylapathite chromatography, and chromatofocusing.
- Affinity chromatography involves the use of a packing material which has been chemically modified by attaching a compound with a specific affinity for desired molecules, primarily biological compounds.
- the packing material used must be inert and easily modified. Agarose is the most common substance used.
- the ligands, or "affinity tails", that are inserted into the matrix can be genetically engineered to possess a specific affinity.
- affinity chromatography In a process similar to ion exchange chromatography, the desired molecules adsorb to the ligands on the matrix until a solution of high salt concentration or low pH is passed through the column (elution). Elution causes desorption of the molecules from the ligands, and they are released from the column.
- Immobilized metal affinity chromatography involves retaining proteins and peptides via accessible Tip and His residues.
- the matrix is attached to a metal chelator, and the chelated metal interacts with Tip and His via a non-covalent bond.
- the more common used metals are Cu++, Ni++, Zn++.
- Retained proteins are eluted by pH modification, EDTA metal complexing or, preferably, using a competition ligand gradient.
- the more common competition ligand is imidazol.
- Dye-ligand affinity chromatography involves the use of immobilized dye linked to a chromatography matrix.
- the dye ligand mainly polyaromatic sulfonated dyes, are able to replace natural coenzyme ligands, ensuring adsorption of proteins containing such coenzymes.
- Some dye- ligand matrices are commercially available. For an extensive list of media and chromatography conditions, see “Dye-Ligand Affinity Chromatography" J. Kirchberger and H-J. B ⁇ hme, in “Protein liquid chromatography", M. Kastner Ed., 2000, p 415-448, Elsevier.
- Hydrophobic interaction chromatography involves interaction between hydrophobic surface areas of proteins and a mild hydrophobic ligand, immobilized on a chromatography media. Protein adsorption is favored by high concentrations of salts and elution is performed with a negative salt gradient, from higher to lower salts concentration. Preferred salts are ammonium sulfate, sodium sulfate or sodium chloride. It is also possible to use solvents for highly hydrophobic proteins elution. For an extensive list of media and chromatography conditions, see “Hydrophobic Interaction chromatography", L.R. Jacob, in “Protein liquid chromatography", M. Kastner Ed., 2000, p 235-269, Elsevier.
- Hydroxylapathite chromatography in contrast to other chromatography technique, is based on interaction with a mineral matrix.
- the media is a crystalline form of calcium phosphate, which adsorbs proteins on their surface.
- the separation mechanism involved is not well understood although the matrix has positive (Ca++) and negative charges (P0 4 3" ).
- Hydroxylapathite chromatography W.R. Deppert and R. Lukacin, in “Protein liquid chromatography", M. Kastner Ed., 2000, p 271-299, Elsevier.
- Chromatofocusing ensures the separation of proteins according to their pi.
- the media particular ion exchange media optimized for this purpose, binds amphoteric molecules (ampholines).
- ampholines amphoteric molecules
- the distribution of ampholines induces a pH gradient in the column and the separation principle is near those of electrofocusing, without the need of an electric field.
- This technique requires special media and buffer solutions.
- chromatographic separation involves identifying or selecting a particular medium or coated medium, and an optimum solvent, solvent flow rate, pH, ionic concentrations and other environmental conditions, such that the starting mixture will separate into a number of relatively narrow bands and such that biomolecules (e.g. proteins) or mixtures of biomolecules sharing certain physical properties pass, or may be made to pass, as a distinct output.
- biomolecules e.g. proteins
- biomolecules sharing certain physical properties pass, or may be made to pass, as a distinct output.
- an appropriate set of separation conditions for a particular biological fluid sample which may have an as yet undetermined dynamic range and protein content, can be optimized or selected such that an appropriate chromatographic separation is achieved.
- This system is able to separate biomolecules into large numbers of distinct fractions with minimal overlap of biomolecules between the fractions.
- the system is also adapted to allow the separation of low abundance biomolecules, including proteins present at subpicomolar concentrations in a fluid sample.
- the transport of material in a separation column proceeds on a macroscopic level by flow past and between the grains or pellets of the chromatography medium, while the degree of separation and column capacity are governed more by the rates at which the particular components diffuse along branching paths into and out of pores in the medium, and are repeatedly adsorbed and released along the diffusion path.
- the degree of separation and column capacity are governed more by the rates at which the particular components diffuse along branching paths into and out of pores in the medium, and are repeatedly adsorbed and released along the diffusion path.
- a selected characteristic is determined using a previously established criterion for identification, for example, a characteristic absorbance measured at a given wavelength
- any step may be run m parallel on a number of similar columns
- This can be used for example to process large samples with a high throughput, by removing the need, for aliquots of a sample, to run them one after the other on the same apparatus They can be run simultaneously m parallel in a number of apparati similar to each other
- the ultimate goal is to separate components of a protein mixture by exploiting the benefits of chromatographic techniques
- Objects of the invention include multi-dimensional analysis to enhance resolving power of a chromatographic system coupled to means for the detection and identification of proteins in complex mixtures of body fluids
- any instrument, method, process, etc can be utilized to determine the identity of proteins in a sample
- a preferred method of obtaining identity is by mass spectrometry, where protein molecules in a sample are ionized and then the resultant mass and charge of the protein ions are detected and determined
- the protein be converted to a gas-ion phase
- Various methods of protein ionization are useful, including, e g , fast ion bombardment (FAB), plasma desorption, laser desorption, thermal desorption, preferably, electrospray ionization (ESI) and matrix-assisted laser desorption iomzation (MALDI)
- FAB fast ion bombardment
- ESI electrospray ionization
- MALDI matrix-assisted laser desorption iomzation
- Many different mass analyzers are available for peptide and protein analysis, including, but not limited to, Time-of-Fhght (TOF), ion trap (ITMS), Fourier transform ion cyclotron (FTMS), quadrupole ion trap, and sector (electric and/or magnetic) spectrometers See, e g , U S Pat No 5,572,025 for an ion-trap MS
- Mass analyzers can be used alone, or in combination with other mass analyzers m tandem mass spectrometers In the latter case, a first mass analyzer can be use to separate the protein ions (precursor ion) from each other and determine the molecular weights of the various protein constituents in the sample A second mass analyzer can be used to analyze each separated constituents, e g , by fragmenting the precursor ions into product ions by using, e g an inert gas Any desired combination of mass analyzers can be used, including, e.g., triple quadrupoles, tandem time-of-flights, ion traps, and/or combinations thereof.
- detectors can be used to detect the protein ions.
- destructive detectors can be utilized, such as ion electron multipliers or cryogenic detectors (e.g., U.S. Pat. No. 5,640,010 ).
- non-destructive detectors can be used, such as ion traps which are used as ion current pick-up devices in quadrupole ion trap mass analyzers or FTMS.
- ion traps which are used as ion current pick-up devices in quadrupole ion trap mass analyzers or FTMS.
- MALDI-TOF a number of sample preparation methods can be utilized including, dried droplet (Karasand Hillenkamp, Anal.
- a liquid-chromatography tandem mass spectrometer for the analysis of digested proteins, a liquid-chromatography tandem mass spectrometer (LC -MS-MS) is used.
- This system provides an additional stage of sample separation via use of a liquid chromatograph followed by tandem mass spectrometry.
- Figure 2 shows a flowchart depicting the steps carried out in a preferred aspect of the invention for fractions obtained from the second reverse phase HPLC column (RP2) as discussed above and in Example 1.
- RP2 reverse phase HPLC column
- a protein eluted from a column according to the system of the invention is analyzed using both MS and MS-MS analysis. For example, a small portion of intact proteins eluting from RP2 may be diverted to online detection using LC-ESI MS.
- the proteins are aliquoted on a number of plates allowing digestion or not with trypsin, preparation for MALDI-MS as well as for ESI-MS, as well as preparation of the MALDI plates with different matrices.
- the methods thus allow, in addition to information on intact mass, to conduct an analysis by both peptide mass fingerprinting and MS-MS techniques.
- the methods described herein of separating and fractionating proteins provide individual proteins or fractions containing small numbers of distinct proteins. These proteins can be identified by mass spectral determination of the molecular masses of the protein and peptides resulting from the fragmentation thereof. Making use of available information in protein sequence databases, a comparison can made between proteolytic peptide mass patterns generated in silico, and experimentally-observed peptide masses. A "hit-list" can be compiled, ranking candidate proteins in the database, based on (among other criteria) the number of matches between the theoretical and experimental proteolytic fragments.
- Several Web sites are accessible that provide software for protein identification on-line, based on peptide mapping and sequence database search strategies (e.g., http://www.expasy.ch).
- Data collected from a mass spectrometer typically comprises the intensity and mass to charge ratio for each detected event.
- Spectral data can be recorded in any suitable form, including, e.g., graphical, numerical, or electronic formats, either in digital or analog form.
- Spectra are preferably recorded in a storage medium, including, e.g., magnetic, such as floppy disk, tape, or hard disk; optical, such as CD-ROM or laser-disc; or, ROM-CHIPS.
- the mass spectrum of a given sample typically provides information on protein intensity, mass to charge ratio, and molecular weight.
- the molecular weights of proteins in the sample are used as a matching criterion to query a database.
- the molecular weights are calculated conventionally, e.g., by subtracting the mass of the ionizing proton for singly-charged protonated molecular ions, by multiplying the measured mass-overcharge-ratio by the number of charges for multiply-charged ions and subtracting the number of ionizing protons.
- databases are useful in accordance with the present invention.
- Useful databases include databases containing genomic sequences, expressed gene sequences, and/or expressed protein sequences.
- Preferred databases contain nucleotide sequence-derived molecular masses of proteins present in a known organism, organ, tissue, or cell-type.
- ORF open reading frames
- ORF open reading frames
- Several publicly accessible databases are available, including, the SwissPROT/TrEMBL database (http://www.expasy.ch).
- a mass spectrometer is equipped with commercial software that identifies peaks above a certain threshold level, calculates mass, charge, and intensity of detected ions. Correlating molecular weight with a given output peak can be accomplished directly from the spectral data, i.e., where the charge on an ion is one and the molecular weight is therefore equal to the numerator value minus the mass of the ionizing proton.
- protein ions can be complexed with various counter-ions and adducts, such as N, C, and K'. In such a case, it would be expected that a given protein ion would exhibit multiple peaks, such as a triplet, representing different ionic states (or species) of the same protein.
- post-translation processing may have to be considered.
- processing events including, proteolytic processing, removal of N-terminal methionine, acetylation, methylation, glycosylation, phosphorylation, etc.
- a database can be queried for a range of proteins which match the molecular mass of the unknown.
- the range window can be determined by the accuracy of the instrument, the method by which the sample was prepared, etc. Based on the number of hits (where a hit is match) in the spectrum, the unknown protein or peptide is identified or classified.
- the chromatographic separations described herein results in protein fractions (116) from which lower molecular weight proteins and peptides (e.g. preferably having molecular weight of less than e.g. 30kD, 20kD or 15kD) are identified.
- lower molecular weight proteins and peptides e.g. preferably having molecular weight of less than e.g. 30kD, 20kD or 15kD
- the methods and systems of the invention combine said method for separating lower molecular weight proteins with a method for separating higher molecular weight proteins.
- the methods of the invention based on chromatographic separation further comprise separating proteins from a biological sample using two-dimensional electrophoretic means.
- the biological fluid sample to be separated using said two dimensional electrophoresis based method may or may not be pretreated so as to enrich in higher molecular weight proteins, since low molecular weight proteins can flow through the electrophoresis gel and be concentrated at one end without significantly impeding separation of higher molecular weight proteins.
- a fluid sample is treated so as to selectively remove at least one abundant protein as described above, preferably by passage over an affinity chromatography column.
- abundant proteins include human serum albumin and immunoglobulins .
- a fluid sample is then subjected to 2-dimensional (2D) gel electrophoresis in order to separate proteins for subsequent detection, preferably by MS methods.
- 2D gel electrophoresis preferably by MS methods.
- a pooled biological sample is divided into two or more portions by volume as described above (e.g. having substantially equal protein composition). At least one of the portions is subjected to 2D gel electrophoresis, while at least one of the portions is subjected to liquid chromatographic separation as described above.
- the portion of biological sample subjected to 2D gel electrophoresis is not first subjected to gel filtration chromatography.
- a portion of sample subjected to size exclusion chromatography to remove proteins below 20 kD is subsequently analyzed by 2D gel electrophoresis.
- Protein samples to be analyzed using 2-D electrophoresis are typically solubilized in an aqueous, denaturing solution such as 9M urea, 2% NP-40 (a non-ionic detergent), 2% of a pH 8-10.5 ampholyte mixture and 1% dithiothreitol (DTT).
- aqueous, denaturing solution such as 9M urea, 2% NP-40 (a non-ionic detergent), 2% of a pH 8-10.5 ampholyte mixture and 1% dithiothreitol (DTT).
- the urea and NP-40 serve to dissociate complexes of proteins with other proteins and with DNA, RNA, etc.
- the ampholyte mixture serves to establish a high pH (9) outside the range where most proteolytic enzymes are active, thus preventing modification of the sample proteins by such enzymes in the sample, and also complexes with DNA present in the nuclei of sample cells, allowing DNA-binding proteins to be released while preventing the DNA from swelling into a viscous gel that interferes with IEF separation.
- the purpose of the DTT is to reduce disulfide bonds present in the sample proteins, thus allowing them to be unfolded and assume an open structure optimal for separation by denaturing IEF.
- Samples of tissues for example, are solubilized by rapid homogenization in the solubilizing solution, after which the sample is centrifuged to pellet insoluble material and DNA, and the supernatant collected for application to the IEF gel.
- cysteine residues will be come oxidized to cysteic acid or recombine and thus stabilize refolded, not fully denatured protein structures during the run, it is desirable to chemically derivatize the cysteines before analysis. This is typically accomplished by alkylation to yield a less reactive cysteine derivative.
- an IEF gel When used as part of a typical 2-D procedure, an IEF gel is applied along one exposed edge of such a slab gel and the proteins it contains migrate into the gel under the influence of an applied electric field.
- the IEF gel may be equilibrated with solutions containing SDS, buffer and thiol reducing agents prior to placement on the SDS gel, in order to ensure that the proteins the IEF gel contains are prepared to begin migrating under optimal conditions, or else this equilibration may be performed in situ by surrounding the gel with a solution or gel containing these components after it has been placed in position along.the slab's edge.
- a slab gel affixed to a Gelbond sheet is typically run in a horizontal position, lying flat on a horizontal cooling plate with the Gelbond sheet down and the unbonded surface up.
- Electrode wicks communicating with "liquid buffer reservoirs, or bars of buffer-containing gel, are placed on opposite edges of the slab to make electrical connections for the run, and samples are generally applied onto the top surface of the slab (as in the instructions for the Pharmacia ExcelGels). It is current practice to detect proteins in 2-D gels either by staining the gels or by exposing the gels to a radiosensitive film or plate (in the case of radioactively labeled proteins). Staining methods include dye-binding (e.g., Coomassie Brilliant Blue), silver stains (in which silver grains are formed in protein-containing zones), negative stains in which, for example, SDS is precipitated by Zn ions in regions where protein is absent, or the proteins may be fluorescently labeled. In each case, images of separated protein spot patterns can be acquired by scanners, and this data reduced to provide positional and quantitative information on sample protein composition through the action of suitable computer software.
- dye-binding e.g., Coomassie Brilliant Blue
- silver stains in which silver grains
- Example 1 Separation Protocol for a starting volume of 2500 ml
- 125 ml frozen plasma were defrost and filtered on 0.45 ⁇ m sterile filter in a sterile hood.
- Filtrate was injected on two inline columns of respectively 300 ml of HSA ligand Sepharose fast Flow column (Amersham, Upsala, Sweden), 5cm ID, 15 cm length; and 100 ml Protein G Sepharose fast Flow column (Amersham, Upsala, Sweden), 5 cm ID, 5 cm length. Columns were equilibrated and washed with 50 mM P04 buffer, pH 7.1, 0.15M NaCl.
- Step 2 Gel Filtration / Reverse Phase Capture step
- Sample from step 1 was defrost and filtered on 0.45 ⁇ m sterile filter in a sterile hood.
- Low molecular weight proteins ( ⁇ 20 kDa) were oriented to in line reverse phase capture column: 50 ml PLRPS 100 angstroms (Polymer labs, UK). The three-way valve controlling injection on PLRPS column was switched at a cut-off of 33 mAU (280 nm) to send gel filtration eluate into reverse phase capture column. This cut-off value was established first by SDS-PAGE to provide an estimated range of OD values and then, by evaluating three cut-off values (high, median and low values of OD range). The cut-off value was chosen to maximize the low molecular weight protein obtained, with a low molecular protein proportion of at least 85%. Low molecular weight proteins and peptides were eluted from reverse phase capture PLRPS column by one column volume gradient of 0.1% TFA, 80% CH3CN in water.
- Eluate fractions (50 ml) were frozen until next step. 20 runs were performed. At the end of this step, all reverse phase eluates were defrost, pooled (1 liter) and shared in 7 polypropylene containers (143 ml). Containers were kept at -20°C until use for next step.
- Sample was injected on a 100 ml Source 15S column (Amersham, Upsala, Sweden), 35 mm ID, 100 mm length. Column was equilibrated and washed with buffer A. Flow rate was 10 ml/min.
- each 18 cation exchange fractions was reduced with dithioerythritol (DTE, 30 mM, 3 hours at 37°C) and alkylated with iodoacetamid (120 mM, 1 hour 25°C in the dark). The latter reaction was stopped with the addition of DTE (30 mM) followed by acidification (TFA, 0.1%). The fractions were then injected on an Uptispher C8, 5 ⁇ m, 300 angstroms column (Interchim, France), 21 mm ID, 150 mm length. Injection was performed with a 10 ml/min flow rate.
- Step 5 Reverse Phase HPLC Fractionation 2 Dried samples from step 4 were resuspended in 1 ml of solution A (0.03% TFA in water) and injected on a Vydac LCMS C4 column, 5 micrometers, 300 angstroms (Vydac, USA), 4.6 mm ID, 150 mm length. Flow rate was 0.8 ml/min.
- 96-well plates (DWP) are recovered and subjected to two sequential concentration steps Volumes are concentrated from 0 8 ml to about 50 microl per well by drying with a SpeedVac, and then resolubihzed to ca 200 microl and reconcentrated to about 50 microl per well, and stored at +4 C Proteins are then digested by re-buffe ⁇ ng, adding trypsin to the wells, sealing and incubating the plates at 37 C for 12 hours, followed by quenching Quenching is accomplished by bringing the pH to 2 with formic acid The concentration of trypsin to be added to the wells was adjusted based on the OD at 280 nm recorded for each particular fraction This ensures an optimal use of trypsm and a complete digestion of the most concentrated fractions Automated spotting devices (Bruker MALDI sample prep Robots) are used to deposit a volume from each well, pre- mixed with a HCCA matrix onto a MALDI plate together with sensitivity and mass calibration standards MALDI plates are
- SY14 Schot-Knappe et al, J. Exp. Med., 183 (1996) 295-299
- IBP3 Zapf et al ; J. Biol.
- Figures 3 to 5 highlight the identification and characterization of leptin from human plasma sample by the method of the invention.
- Figure 3 shows the MALDI-MS peptide mass for Leptin and
- Figure 4 shows results from the MS/MS characterization.
- Figure 5 displays a summary of the portions of the sequence of leptin that were characterized by mass spectrometry in this example.
- Example 3 Separation Protocol for a starting volume of 500 ml
- 125 ml frozen plasma were defrost and filtered on 0.45 ⁇ m sterile filter in a sterile hood.
- Filtrate was injected on two inline columns of respectively 300 ml of HSA ligand Sepharose fast Flow column (Amersham, Upsala, Sweden), 5cm ID, 15 cm length; and 100 ml Protein G Sepharose fast Flow column (Amersham, Upsala, Sweden), 5 cm ID, 5 cm length.
- Step 2 Gel Filtration / Reverse Phase Capture step
- Sample from step 1 was defrost and filtered on 0.45 ⁇ m sterile filter in a sterile hood.
- Low molecular weight proteins ( ⁇ 20 kDa) were oriented to in line reverse phase capture column: 50 ml PLRPS 100 angstroms (Polymer labs, UK). The three-way valve controlling injection on PLRPS column was switched at a cut-off of 33 mAU (280 nm) to send gel filtration eluate into reverse phase capture column. This cut-off value was established first by SDS-PAGE to provide an estimated range of OD values and then, by evaluating three cut-off values (high, median and low values of OD range). The cut-off value was chosen to maximize the low molecular weight protein obtained, with a low molecular protein proportion of at least 85%. Low molecular weight proteins and peptides were eluted from reverse phase capture PLRPS column by one column volume gradient of 0.1% TFA, 80% CH3CN in water.
- Eluate fractions (50 ml) were frozen until next step. 4 runs were performed. At the end of this step, all reverse phase eluates were defrost, pooled (200 ml) and shared in 2 polypropylene containers. Containers were kept at -20°C until use for next step.
- Sample was injected on a 100 ml Source 15S column (Amersham, Upsala, Sweden), 35 mm ID, 100 mm length. Column was equilibrated and washed with buffer A. Flow rate was 10 ml/min.
- each 12 cation exchange fractions was reduced with dithioerythritol (DTE, 30 mM, 3 hours at 37°C) and alkylated with iodoacetamid (120 mM, 0.5 hour 37°C in the dark). The latter reaction was stopped with the addition of DTE (30 mM) followed by acidification (TFA, 0.1%). The fractions were then injected on an Uptispher C8, 5 ⁇ m, 300 angstroms column (Interchim, France), 21 mm ID, 150 mm length. Injection was performed with a 10 ml/min flow rate.
- DTE dithioerythritol
- TFA acidification
- Step 5 Reverse Phase HPLC Fractionation 2 Dried samples from step 4 were resuspended in 1 ml of solution A (0.03% TFA in water) and injected on a Vydac LCMS C4 column, 3 micrometers, 300 angstroms (Vydac, USA), 4.6 mm ID, 100 mm length. Flow rate was 0.8 ml/min.
- 96-well plates (DWP) are recovered and subjected to two sequential concentration steps. Volumes are concentrated from 0.8 ml to about 50 microl per well by drying with a SpeedVac, and then resolubilized to ca. 200 microl and reconcentrated to about 50 microl per well, and stored at +4 C. Proteins are then digested by re-buffering, adding trypsin to the wells, sealing and incubating the plates at 37 C for 12 hours, followed by quenching. Quenching is accomplished by bringing the pH to 2 with formic acid. The concentration of trypsin to be added to the wells was adjusted based on the OD at 280 nm recorded for each particular fraction.
- Automated spotting devices (Bruker MALDI sample prep. Robots) are used to deposit a volume from each well, pre- mixed with a HCCA matrix onto a MALDI plate together with sensitivity and mass calibration standards.
- MALDI plates are analyzed using a Bruker Reflex III MALDI MS device. Contents from each well of the 96 well plates are analyzed LC-ESI-MS-MS Bruker Esquire 3000 plus ESI Ion-Trap MS devices.
- Example 4 Separation Protocol for a starting volume of 10 ml
- Filtrate was injected on two inline columns of respectively 30 ml of HSA ligand Sepharose fast Flow column (Amersham, Upsala, Sweden), 1.6 cm ID, 15 cm length; and 10 ml Protein G Sepharose fast Flow column (Amersham, Upsala, Sweden), 1.6 cm ID, 5 cm length.
- Non-retained fraction (35 ml) was frozen until second step.
- Step 2 Gel Filtration / Reverse Phase Capture step
- Sample from step 1 was defrost and filtered on 0.45 ⁇ m sterile filter in a sterile hood. Filtrate was injected on three in line gel filtration columns: 3 X 0.6 litres Superdex 75 (Amersham, UK) column, 4.4 cm ID, 40 cm length. Columns were equilibrated with 50mM P04 buffer pH 7.4, 0.1 M NaCl, 8M urea. Hydrophobic impurities were retained on a reverse phase precolumn: 15 ml PLRPS (Polymer Labs, UK). Precolumn was switched for sample injection. Gel filtration was performed at a flow rate of 4 ml/min.
- Low molecular weight proteins ( ⁇ 20 kDa) were oriented to in line reverse phase capture column: 5 ml PLRPS 100 angstroms (Polymer labs, UK). The three-way valve controlling injection on PLRPS column was switched at a cut-off of 33 mAU (280 nm) to send gel filtration eluate into reverse phase capture column. This cut-off value was established first by SDS-PAGE to provide an estimated range of OD values and then, by evaluating three cut-off values (high, median and low values of OD range). The cut-off value was chosen to maximize the low molecular weight protein obtained, with a low molecular protein proportion of at least 85%. Low molecular weight proteins and peptides were eluted from reverse phase capture PLRPS column by one column volume gradient of 0.1% TFA, 80% CH3CN in water. Eluate fraction (5 ml) was frozen until next step.
- Sample was injected on a 10 ml Source 15S column (Amersham, Upsala, Sweden), 1 cm ID, 10 cm length. Column was equilibrated and washed with buffer A. Flow rate was 1 ml/min.
- Proteins and peptides were eluted with step gradient from 100% buffer A until 100 % buffer B (buffer A containing IM NaCl): 3 column volumes 7.5% B (75 mM NaCl) 3 column volumes 10% B (100 mM NaCl) 3 column volumes 17.5% B (175 mM NaCl) 2 column volumes 22.5% B (225 mM NaCl) 2 column volumes 27.5% B (275 mM NaCl) 2 column volumes 100% B (1 M NaCl)
- each 15 cation exchange fractions was reduced with dithioerythritol (DTE, 30 mM, 2 hours at 37°C) and alkylated with iodoacetamid (120 mM, 30 min at 37°C in the dark, under agitation).
- DTE dithioerythritol
- iodoacetamid 120 mM, 30 min at 37°C in the dark, under agitation.
- the latter reaction was stopped with the addition of DTE (30 mM) followed by acidification (TFA, 0.1%>).
- the fractions were then injected on a Vydac C4, 3 ⁇ m, 300 angstroms column (Vydac, CA, USA), 4.6 mm ID, and 100 mm length.
- DWP 96-well deep well plates
- a small proportion (2.5 %) of the volume is diverted to online analysis using LC-ESI-MS (Bruker Esquire).
- 96-well plates (DWP) are recovered and subjected to concentration step. Volumes are concentrated from 0.8 ml to about 50 microl per well by drying with a SpeedVac and proteins are then digested by re-buffering, adding trypsin to the wells, sealing and incubating the plates at 37 C for 12 hours. The concentration of trypsin to be added to the wells was adjusted based on the OD at 210 nm recorded for each particular fraction.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03788440A EP1535053A2 (en) | 2002-08-16 | 2003-08-13 | Multi-dimensional chromatography system for proteomics |
AU2003258208A AU2003258208A1 (en) | 2002-08-16 | 2003-08-13 | Multi-dimensional chromatography system for proteomics |
CA002494998A CA2494998A1 (en) | 2002-08-16 | 2003-08-13 | Multi-dimensional chromatography system for proteomics |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40390902P | 2002-08-16 | 2002-08-16 | |
US60/403,909 | 2002-08-16 | ||
GB0221469.0 | 2002-09-16 | ||
GB0221469A GB0221469D0 (en) | 2002-09-16 | 2002-09-16 | Multi-dimensional chromatography system for proteomics |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004017040A2 true WO2004017040A2 (en) | 2004-02-26 |
WO2004017040A3 WO2004017040A3 (en) | 2004-10-21 |
Family
ID=31889686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/025367 WO2004017040A2 (en) | 2002-08-16 | 2003-08-13 | Multi-dimensional chromatography system for proteomics |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1535053A2 (en) |
AU (1) | AU2003258208A1 (en) |
CA (1) | CA2494998A1 (en) |
WO (1) | WO2004017040A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528368B2 (en) | 2006-03-23 | 2009-05-05 | Protea Biosciences, Inc. | Electrospray ionization process and add-on device with sample injection tip |
US7641778B2 (en) | 2006-03-23 | 2010-01-05 | Protea Biosciences, Inc. | Gel electroelution and sample separation devices and associated processes |
US8074494B2 (en) | 2007-12-10 | 2011-12-13 | Proxeon Biosystems A/S | Plugged flow 2D chromatography |
WO2018127515A1 (en) * | 2017-01-06 | 2018-07-12 | Technische Universität Braunschweig | Method for two-dimensional protein separation and protein-separating device |
WO2019152352A1 (en) * | 2018-01-31 | 2019-08-08 | Regeneron Pharmaceuticals, Inc. | A dual-column lc-ms system and methods of use thereof |
CN114088861A (en) * | 2021-10-27 | 2022-02-25 | 上海市食品药品检验研究院 | Method for detecting enterotoxin C in milk by using multi-dimensional liquid chromatography-mass spectrometry |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103063753B (en) * | 2012-08-31 | 2015-07-29 | 西安奥岚科技开发有限责任公司 | For multidimensional liquid chromatographic separation system and the separation method of Protein Separation |
-
2003
- 2003-08-13 WO PCT/US2003/025367 patent/WO2004017040A2/en not_active Application Discontinuation
- 2003-08-13 AU AU2003258208A patent/AU2003258208A1/en not_active Abandoned
- 2003-08-13 CA CA002494998A patent/CA2494998A1/en not_active Abandoned
- 2003-08-13 EP EP03788440A patent/EP1535053A2/en not_active Withdrawn
Non-Patent Citations (7)
Title |
---|
ADKINS J.N. ET AL.: 'Toward a human blood serum proteome' MOLECULAR AND CELLULAR PROTEOMICS vol. 1, 13 November 2002, pages 947 - 955, XP002975238 * |
ARNAUD P. ET AL.: 'Purification of proteins by subtraction affinity chromatography' PROTIDES OF THE BIOLOGICAL FLUIDS vol. 26, 1979, pages 649 - 652 * |
FERGUSON P.L., SMITH R.D.: 'Proteome analysis by mass spectrometry' ANNU. RE. BIOPHYS. STRUCT. vol. 32, 24 January 2003, pages 399 - 424, XP002975239 * |
'Multidimensional chromatography', [Online] 18 July 2002, XP002975235 Retrieved from the Internet: <URL:http://www.chem.agilent.com/cag/prod/l c/Application-multi.pdf> * |
REGNIER F. ET AL.: 'Multidimensional chromatography and the signature peptide approach to proteomics' LCGC vol. 19, no. 2, February 2001, page 200, 202, 204, 206, 208, 210, 212, 213, XP002975237 * |
WOLTERS D.A. ET AL.: 'An automated multidimensional protein identification technology for shotgun proteomics' ANAL. CHEM. vol. 73, 2001, pages 5683 - 5690, XP002975236 * |
ZHANG Z. ET AL.: 'Multiple separations facilitate identification of protein variants by mass spectrometry' PROTEOMICS vol. 1, 2001, pages 1001 - 1009, XP009016604 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528368B2 (en) | 2006-03-23 | 2009-05-05 | Protea Biosciences, Inc. | Electrospray ionization process and add-on device with sample injection tip |
US7641778B2 (en) | 2006-03-23 | 2010-01-05 | Protea Biosciences, Inc. | Gel electroelution and sample separation devices and associated processes |
US8074494B2 (en) | 2007-12-10 | 2011-12-13 | Proxeon Biosystems A/S | Plugged flow 2D chromatography |
WO2018127515A1 (en) * | 2017-01-06 | 2018-07-12 | Technische Universität Braunschweig | Method for two-dimensional protein separation and protein-separating device |
WO2019152352A1 (en) * | 2018-01-31 | 2019-08-08 | Regeneron Pharmaceuticals, Inc. | A dual-column lc-ms system and methods of use thereof |
CN111699392A (en) * | 2018-01-31 | 2020-09-22 | 瑞泽恩制药公司 | Dual column LC-MS system and method of use |
US10908166B2 (en) | 2018-01-31 | 2021-02-02 | Regeneron Pharmaceuticals, Inc. | Dual-column LC-MS system and methods of use thereof |
JP2021513060A (en) * | 2018-01-31 | 2021-05-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Dual column LC-MS system and how to use it |
US11435359B2 (en) | 2018-01-31 | 2022-09-06 | Regeneron Pharmaceuticals, Inc. | Dual-column LC-MS system and methods of use thereof |
US11740246B2 (en) | 2018-01-31 | 2023-08-29 | Regeneron Pharmaceuticals, Inc. | Dual-column LC-MS system and methods of use thereof |
CN114088861A (en) * | 2021-10-27 | 2022-02-25 | 上海市食品药品检验研究院 | Method for detecting enterotoxin C in milk by using multi-dimensional liquid chromatography-mass spectrometry |
Also Published As
Publication number | Publication date |
---|---|
AU2003258208A1 (en) | 2004-03-03 |
CA2494998A1 (en) | 2004-02-26 |
EP1535053A2 (en) | 2005-06-01 |
AU2003258208A8 (en) | 2004-03-03 |
WO2004017040A3 (en) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nägele et al. | 2D-LC/MS techniques for the identification of proteins in highly complex mixtures | |
Fournier et al. | Multidimensional separations-based shotgun proteomics | |
Shi et al. | The role of liquid chromatography in proteomics | |
Cooper et al. | Recent advances in capillary separations for proteomics | |
Hille et al. | Possibilities to improve automation, speed and precision of proteome analysis: A comparison of two‐dimensional electrophoresis and alternatives | |
US6358692B1 (en) | High speed, automated, continuous flow, multi-dimensional molecular selection and analysis | |
Temporini et al. | Integrated analytical strategies for the study of phosphorylation and glycosylation in proteins | |
AU2002341862B2 (en) | Controlling isotope effects during fractionation of analytes | |
Tang et al. | Recent development of multi-dimensional chromatography strategies in proteome research | |
AU2002341862A1 (en) | Controlling isotope effects during fractionation of analytes | |
Mahboob et al. | Is isolation of comprehensive human plasma peptidomes an achievable quest? | |
CA2465214A1 (en) | Methods for monitoring polypeptide production and purification using surface enhanced laser desorption/ionization mass spectrometry | |
Nice et al. | Use of multidimensional separation protocols for the purification of trace components in complex biological samples for proteomics analysis | |
EP2545370B1 (en) | Method for recognition and quantification of multiple analytes in a single analysis | |
WO2004017040A2 (en) | Multi-dimensional chromatography system for proteomics | |
CA2863635A1 (en) | Selector based recognition and quantification system and method for multiple analytes in a single analysis | |
Léger et al. | Solid-phase hexapeptide ligand libraries open up new perspectives in the discovery of biomarkers in human plasma | |
Nühse et al. | Isolation of phosphopeptides by immobilized metal ion affinity chromatography | |
EP1748297B1 (en) | Method for analysing naturally occuring peptides and small proteins using mass spectrometry | |
Alhendi | A Review: Protein Identification by LC-MS: Principles, Instrumentation, and Applications. | |
US20150105280A1 (en) | Selector based recognition and quantification system and method for multiple analytes in a single analysis | |
Restuccia et al. | pI-based fractionation of serum proteomes versus anion exchange after enhancement of low-abundance proteins by means of peptide libraries | |
Zheng et al. | Elucidation of peptide metabolism by on‐line immunoaffinity liquid chromatography mass spectrometry | |
Millea et al. | Subproteomics in analytical chemistry: Chromatographic fractionation techniques in the characterization of proteins and peptides | |
Hart et al. | LC–tandem MS in proteome characterization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase in: |
Ref document number: 2494998 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003788440 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003788440 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003788440 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |